Activities of poloxamer CRL-1072 against Mycobacterium avium in macrophage culture and in mice

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 12, 1999, Pages 2898-2903

  Jagannath, Chinnaswamy ^a   Emanuele, Martin R ^b   Hunter, Robert L ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b CytRx Corporation   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CLARITHROMYCIN; CLINDAMYCIN; CRL 1072; POLOXAMER; RIFAMPICIN; STREPTOMYCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MACROPHAGE; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOCYTE; MOUSE; MYCOBACTERIUM INTRACELLULARE AVIUM; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0032795716     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.12.2898     Document Type: Article

References (43)

1. Araujo, F. G., and T. Slifer. 1995. Nonionic block copolymers potentiate activities of drugs for treatment of infections with Toxoplasma gondii. Antimicrob. Agents Chemother. 39:2696-2701.
2. Baker, S., J. Gunn, and R. Morona. 1999. The Salmonella typhi melittin resistance gene pqaB affects intracellular growth in PMA-differentiated U937 cells, polymyxin B resistance and lipopolysaccharide. Microbiology 145:367-378.
3. Bates, J. H. 1996. Mycobacterium avium disease: progress at last. Am. J. Respir. Crit. Care Med. 153:1737-1738. (Editorial comment.)
4. Behling, C. A. 1992. Studies on the composition, conformation and function of lipids on the surface of mycobacteria. Ph.D. thesis. Emory University, Atlanta, Ga.
5. Behling, C. A., F. S. Nolte, A. Tinkley, and R. L. Hunter. 1994. The effect of tyloxapol on the surface lipids and biologic activities of BCG. Vaccine Res. 3:1-14.
6. Berenbaum, M. C. 1978. A method of testing synergy with any number of agents. J. Infect. Dis. 137:122-130.
7. Caron, E., J. Liautard, and S. Kohler. 1994. Differentiated U937 cells exhibit increased bactericidal activity upon LPS activation and discriminate between virulent and avirulent Listeria and Brucella species. J. Leukoc. Biol. 56:174-181.
8. Cellier, M., C. Shustik, W. Dalton, E. Rich, J. Hu, D. Malo, E. Schurr, and P. Gros. 1997. Expression of the human NRAMP1 gene in professional primary phagocytes: studies in blood cells and in HL-60 promyelocytic leukemia. J. Leukoc. Biol. 61:96-105.
9. Ceresa, R. J. (ed.). 1976. Block and graft copolymerization, vol. 2. John Wiley & Sons, Inc., London, United Kingdom.
10. Connell, N. D., and H. Nikaido. 1994. Membrane permeability and transport in Mycobacterium tuberculosis, p. 333-352. In B. Bloom (ed.), Tuberculosis. Pathogenesis, protection, and control. American Society for Microbiology, Washington, D.C.
11. Cornforth, J. W., P. Hart, R. Rees, and J. Stock. 1951. Antituberculous effect of certain surface active polyoxyethylene ethers in mice. Nature 168:150-153.
12. Cornforth, J. W., and P. D. Hart. 1968. Mycobacterium tuberculosis in macrophages: effect of certain surfactants and other membrane-active compounds. Science 162:686-689.
13. Cornforth, J. W., P. D. Hart, G. A. Nicholls, R. J. W. Rees, and J. A. Stock. 1955. Antituberculous effects of certain surface active polyoxyethylene ethers. Br. J. Pharmacol. 10:73-86.
14. CytRx Corporation. Data on file. CytRx Corporation, Norcross, Ga.
15. Doucet-Populaire, F., C. Truffot-Pernot, J. Grosset, and V. Jarlier. 1995. Acquired resistance in Mycobacterium avium complex strains isolated from AIDS patients and beige mice during treatment with clarithromycin. J. Antimicrob. Chemother. 36:129-136.
16. Gangadharam, P. R. J., C. K. Edwards, P. Murthy, and P. Pratt. 1983. An acute infection model for Mycobacterium intracellulare disease using beige mice: preliminary results. Am. Rev. Respir. Dis. 127:648-649.
17. Griffith, D. E., B. A. Brown, W. M. Girard, and R. J. Wallace. 1995. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin. Infect. Dis. 21:594-598.
18. Hass, R., I. Prudovsky, and M. Kruhoffer. 1997. Differential effects of phorbol ester on signaling and gene expression in human leukemia cells. Leukoc. Res. 21:589-594.
19. Heifets, L. B. 1991. Drug combinations, p. 90-115. In L. B. Heifets (ed.), Drug susceptibility in chemotherapy of mycobacterial infections. CRC Press, Inc., Boca Raton, Fla.
20. Hunter, R. L., C. Jagannath, A. Tinkley, C. A. Behling, and F. Nolte. 1995. Enhancement of antibiotic susceptibility and suppression of Mycobacterium avium complex growth by poloxamer 331. Antimicrob Agents Chemother. 39:435-439.
21. Jagannath, C., J. K. Actor, and R. L. Hunter. 1998. Induction of nitric oxide in human monocytes and monocyte cell lines by Mycobacterium tuberculosis. Nitric Oxide 2:174-186.
22. Jagannath, C., H. S. Allaudeen, and R. L. Hunter. 1995. Activities of poloxamer CRL8131 against Mycobacterium tuberculosis in vitro and in vivo. Antimicrob. Agents Chemother. 39:1349-1354.
23. Jagannath, C., R. M. Emanuele, and R. L. Hunter. Activity of CRL-1072 against drug resistant strains of Mycobacterium tuberculosis in vitro and in vivo. Int. J. Antimicrobial Agents, in press.
24. Jagannath, C., S. Pai, J. K. Actor, and R. L. Hunter. 1999. CRL-1072 enhances antimycobacterial activity of human macrophages through Interleukin-8. J. Interferon Cytokine Res. 19:67-76.
25. Ji, B., N. Lounis, C. Truffot-Pernot, and J. Grosset. 1994. Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model. Antimicrob. Agents Chemother. 38:2521-2529.
26. Kiley, S., and P. Parker. 1997. Defective microtubule reorganization in phorbol ester-resistant U937 variants: reconstitution of the normal cell phenotype with nocodazole treatment. Cell Growth Differ. 8:231-242.
27. Klemens, S. P., M. S. DeStefano, and M. H. Cynamon. 1992. Activity of clarithromycin against Mycobacterium avium complex infection in beige mice. Antimicrob. Agents Chemother. 36:2413-2417.
28. Krahenbuhl, J. L., Y. Fukutomi, and L. Gu. 1993. Treatment of acute experimental toxoplasmosis with investigational poloxamers. Antimicrob Agents Chemother. 37:2265-2269.
29. Larrick, J., D. Fischer, S. Anderson, and H. Koren. 1980. Characterization of a human macrophage-like cell line stimulated in vitro: a model of macrophage functions. J. Immunol. 125:6-12.
30. Lundsted, L. G., and I. R. Schmolka. 1976. The synthesis and properties of block copolymer polyol surfactants, p. 1-103. In R. J. Ceresa (ed.), Block and graft copolymerization, vol. 2. John Wiley & Sons, Inc., London, United Kingdom.
31. Mor, N., B. Simon, N. Mezo, and L. Heifets. 1995. Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages. Antimicrob. Agents Chemother. 39:2073-2077.
32. Mor, N., J. Vanderkolk, N. Mezo, and L. B. Heifets. 1994. Effects of clarithromycin and rifabutin alone and in combination on intracellular and extracellular replication of Mycobacterium avium. Antimicrob. Agents Chemother. 38:2730-2742.
33. Naik, S. P., W. A. Samsonoff, and R. E. Ruck. 1988. Effects of surface-active agents on drug susceptibility levels and ultrastructure of Mycobacterium avium complex organisms isolated from AIDS patients. Diagn. Microbiol. Infect. Dis. 11:11-19.
34. Nash, K. A., and C. B. Inderlied. 1995. Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. Antimicrob. Agents Chemother. 39:2625-2630.
35. Nettelnbreker, E., H. Zeidler, H. Bartels, U. Dreses-Werringloer, W. Daubener, H. Holtmann, and L. Kohler. 1998. Studies of persistent infection by Chlamydia trachomatis serovar K in TPA-differentiated U937 cells and the role of IFN-gamma. J. Med. Microbiol. 47:141-149.
36. Nikaido, H. 1994. Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science 264:382-388.
37. Nikaido, H., and S. Normack. 1987. Sensitivity of Escherichia coli to various beta-lactams is determined by the interplay of outer membrane and degradation by periplasmic beta-lactamases: a quantitative predictive treatment. Mol. Microbiol. 1:29-36.
38. Sellmayer, A., H. Obermeier, and C. Weber. 1997. Intrinsic cyclooxygenase activity is not required for monocytic differentiation of U937 cells. Cell. Signal. 9:91-96.
39. Shafran, S. D., J. Singer, D. P. Zarowny, P. Phillips, I. Salit, S. L. Walmsley, I. W. Fong, M. J. Gill, A. R. Rachlis, R. G. Lalonde, M. M. Fanning, and C. M. Tsoukas. 1996. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. N. Engl. J. Med. 335:377-383.
40. Sison, J. P., Y. Yao, C. A. Kemper, J. R. Hamilton, E. Brummer, D. A. Stevens, and S. C. Deresinski. 1996. Treatment of Mycobacterium avium complex infection: do the results of in vitro susceptibility tests predict therapeutic outcome in humans? J. Infect. Dis. 173:677-683.
41. Sundstrom, C., and K. Nilsson. 1976. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int. J. Cancer. 17:565-577.
42. Wallace, R. J., B. A. Brown, D. E. Griffith, W. M. Girard, and D. T. Murphy. 1996. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am. J. Respir. Crit. Care Med. 153:1766-1772.
43. Zimmerli, S., S. Edwards, and J. Ernst. 1996. Selective receptor blockade during phagocytosis does not alter the survival and growth of Mycobacterium tuberculosis in human macrophages. Am. J. Respir. Cell. Mol. Biol. 15:760-770.